Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical ManagementShow others and affiliations
2026 (English)In: Clinical Infectious Diseases, ISSN 1058-4838, E-ISSN 1537-6591, Vol. 82, no 5, p. e1045-e1052, article id PMID 9203213Article, review/survey (Refereed) Published
Abstract [en]
Developing shorter treatment regimens for tuberculosis requires careful characterization of the clinical phenotype, which is defined by patient characteristics, radiological extent of disease, mycobacterial burden, drug susceptibility, and host response. Advances in 'omics and model-informed precision dosing, as well as integrated algorithms using artificial intelligence, need to be adapted and validated in clinical trials to improve classification of patients for stratified treatment. When treatment is initiated based on the clinical phenotype, monitoring of treatment response can be improved by quantification of bacterial load, transcriptomic and epigenetic biosignatures for sputum-free monitoring, and assessing disease burden by radiological and symptom scoring tools. Many of these tools are suitable for high-endemic settings. Such integrated monitoring allows prompt drug adjustments for rapid reduction in bacterial load, which prevents development of drug resistance and achieves relapse-free cure even with shorter treatment. This review explores current and future tools for defining and managing clinical tuberculosis phenotypes from a clinical perspective. Treatment monitoring using bacterial quantification and 'omics with model-informed precision dosing may reduce relapse and improve patient selection for stratified shorter regimens.
Place, publisher, year, edition, pages
OXFORD UNIV PRESS INC , 2026. Vol. 82, no 5, p. e1045-e1052, article id PMID 9203213
Keywords [en]
tuberculosis; precision medicine; treatment monitoring; stratified treatment; disease severity
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:liu:diva-220754DOI: 10.1093/cid/ciaf663ISI: 001661560100001PubMedID: 41537599Scopus ID: 2-s2.0-105039464175OAI: oai:DiVA.org:liu-220754DiVA, id: diva2:2032882
Note
Funding Agencies|Swedish Research Council [2019-05912, 2022-05263, 2022-00865, 2022-04041]; Swedish Heart-Lung Foundation [2022-0238, 2022-0148]; Region Ostergoetland, Sweden [ALF 987589, ROE-1005642]; Veni project [09150161910052]; Dutch Research Council (NWO)
2026-01-282026-01-282026-10-13Bibliographically approved